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+ haemopoietic cells in which PCR analyclinically. sis indicated that up to 70% of progenitors were trans-Introduction Anti-tumour chemotherapeutic agents such as temozolomide, BCNU, mitozolomide, chlorozotocin and procarbazine (O 6 -alkylating agents) are or have been used in the treatment of a range of tumour types including small cell lung cancer, Hodgkin's disease, non-Hodgkin's lymphoma, glioma and malignant melanoma. 1 Treatment is complicated by dose limiting toxicity to normal tissues, particularly bone marrow, and by the inherent resistance of some tumours to the agents used. 2, 3 Additionally, the clinical use of O 6 -alkylating agents is associated with a risk of therapy-related malignancy. 4, 5 Resistance to these -beG are to reach their full potential. Indeed, a strategy that combined the pharmacological sensitisation of tumours to chemotherapy with the simultaneous prevention of enhanced toxicity in bone marrow could substantially improve the therapeutic index of a number of chemotherapeutic agents. 16, 17 One approach to this would be to protect human haemopoietic progenitor cells against the biological effects of combined O 6 -beG and O 6 -alkylating agents by retroviral transduction with an engineered form of human ATase (hAT) that is resistant to inactivation by O 6 -beG. 18 We have previously reported the characterisation of two such hAT mutants: one of these (hATPA) was found to be 16 times more resistant to O 6 -beG than the wild-type protein while the other (hATPA/GA) was almost totally refractory to inactivation. 19 Protection of Chinese hamster lung fibroblasts (RJKO) from the toxic effects of combined O 6 -beG and O 6 -alkylating agents via the plasmid-based expression of hATPA/GA has been recently demonstrated. 19 Here we report the development of these studies to achieve protection of granulocyte-macrophage colony-forming cells (GM-CFC) derived from primary human haemopoietic (CD34 + ) and erythroleukaemic progenitor (K562) cells from such combination treatment via retrovirus-mediated expression of hATPA/GA.
Results
Selection of human erythroleukaemic progenitors (K562) expressing hATPA or hATPA/GA using mitozolomide Populations of hATPA-or hATPA/GA-transduced K562 were plated in the presence or absence of 0.65 g/ml mitozolomide. For the unselected cells, transduction efficiencies of 10% and 2% were determined by PCR in colonies derived from cells exposed to LhATPA and LhATPA/GA, respectively. In comparison, a single round of mitozolomide selection resulted in killing of untransduced cells and a population of surviving colonies that were 100% positive by PCR for the presence of LhATPA or LhATPA/GA (data not shown). Therefore, it was possible to achieve selection of a small number of transduced cells on the basis of the retrovirally encoded resistance factor. However, these colonies were not used in the subsequent cytotoxicity studies because of reservations that mitozolomide exposure could have altered the endogenous resistance profiles of these cells.
Protection of human erythroleukaemic progenitors (K562) from O
6 -alkylating agent toxicity in the presence of O 6 -beG For the cytotoxicity studies, clones selected solely on the basis of positivity by PCR without prior exposure to alkylating agents for the presence of LhATPA or LhATPA/GA provirus, respectively, were expanded for ATase assay. Several of those that expressed elevated levels of ATase (Table 1) were chosen for further analysis along with a mock-transduced clone which, as expected, expressed no detectable endogenous ATase. The hATPA/GA clones retained Ͼ95% of their initial ATase activity following exposure to 20 m O 6 -beG while activity in hATPA clones was depleted to about 5% of initial activity under the same conditions (Table 1) . Clonogenic survival assays following exposure to the methylating agent temozolomide (Figure 1a -c) and the chloroethylating agent mitozolomide (Figure 1d -f) were used to determine the resistance, in the presence and absence of 20 m O 6 -beG, of one each of the hATPA and hATPA/GA clones generated by retroviral transduction. The mock-transduced K562 cells were highly sensitive to all of the agents used and treatment with O 6 -beG did not further potentiate cytotoxicity in these cells. In comparison, cells expressing hATPA or hATPA/GA were protected against O 6 -alkylating agent toxicity (P Ͻ 0.001 for both agents). While the degree of protection afforded by either hATPA or hATPA/GA in the absence of O 6 -beG was generally similar with respect to either mitozolomide or chlorozotocin toxicity, for temozolomide the single mutant protein appeared to confer much greater resistance than the double mutant form. Significantly, the sensitivity of cells expressing hATPA/GA to any of the three agents was not increased by pretreatment with O 6 -beG (P Ͻ 0.001). In contrast, the protective effect exerted by hATPA against mitozolomide or chlorozotocin toxicity in the absence of O 6 -beG was dramatically reduced by pretreatment with O 6 -beG (P Ͻ 0.001) which is consistent with the almost complete depletion of hATPA activity by this dose of inactivator (Table 1) . Interestingly, the hATPA expressing cells were not fully sensitised to temozolomide toxicity by a single dose of O 6 -beG but were still significantly resistant relative to controls (P Ͻ 0.01), a situation that we have previously observed. 21 The D 37 values obtained for temozolomide and mitozolomide, as well as for another chloroethylating agent, chlorozotocin (Table 2 ), demonstrated that the retroviral delivery and expression of hATPA/GA can significantly protect human haemopoietic cells against the toxicity of a wide + cells were transduced with LhATPA/GA, exposed to increasing temozolomide concentrations in the presence (10 m) or absence of O 6 -beG and the survival of the GM-CFC determined ( Figure 2a ). As controls, cells were transduced with a retrovirus harbouring the ␣-iduronidase cDNA (LID) 20 and were treated identically and in parallel with LhATPA/GAtransduced cells. Under conditions in which a transduction efficiency of 70% was achieved, as determined by PCR, CD34
+ cells transduced with hATPA/GA were significantly protected (P Ͻ 0.001) against temozolomide toxicity in the presence of O 6 -beG relative to the control cells, which were dramatically sensitised to killing by this combination (LD 10 = 11.2 g/ml and 2.3 g/ml for hATPA/GA and control cells, respectively). At one dose of temozolomide in the presence of O 6 -beG, approximately 35% of the hATPA/GA population survived while LID control cell survival was Ͻ1% under identical conditions. In the absence of O 6 -beG, temozolomide toxicity was only evident at the highest dose analysed and at this concentration significant protection against toxicity was afforded by transduction with the hATPA/GA retrovirus (P Ͻ 0.05 at 16 g/ml, paired t test). In a separate experiment, the hATPA/GA-transduced CD34 + population (transduction efficiency approximately 50%) was significantly protected against the toxicity of the chloroethylating agent mitozolomide (Figure 2b ). Thus exposure of cells to mitozolomide (0.4 g/ml) in the presence of O 6 -beG resulted in 20% survival of the hATPA/GA-transduced cells whereas only 4% of the LID-transduced control cells survived (P Ͻ 0.05). In contrast to the experience with temozolomide, no significant difference was seen between the sensitivity of control and hATPA/GA-transduced cells to killing by mitozolomide in the absence of O 6 -beG (P = 0.77).
Discussion
The efficacy of many chemotherapeutic agents is limited by the inherent resistance of the tumour and/or the sensitivity of normal tissues to these drugs. An additional complication is that the use of many anticancer drugs is associated with a risk of therapy-related malignancy. While dose escalation has resulted in improved tumour kill in some instances, this approach requires intensive supportive care through the acute toxic episodes and as patient survival increases this is likely to lead to an elevation in the frequency of therapy-related malignancies. These problems are particularly well illustrated by the O 6 -alkylating agents. 5 The major determinant of cellular resistance or sensitivity to these agents is the expression of the DNA repair protein ATase and for this reason modulation of the level of this protein has become a clinical objective. 6, 7, 17, 21 A number of approaches have been taken to overcome ATase-mediated tumour resistance and the use of pseudo-substrates such as O 6 -beG is particularly promising although the possibility that this will enhance normal tissue sensitivity may limit its utility. Similarly, retroviral transfer and expression of wild-type hAT in primary murine bone marrow progenitor cells, both in vitro and in vivo, have demonstrated that it is possible to protect these to some extent against the toxic effects of appropriate agents. [22] [23] [24] However, a problem arises in combining the use of O 6 -beG with protection strategies involving hAT: the extreme sensitivity of the wild-type protein to inactivation by O 6 -beG 25 means that any protective effect conferred by gene transfer would be rapidly negated by the use of this inactivator. Gene transfer, using the bacterial homologue of human ATase, ada, which is insensitive to O 6 -beG could offer a solution to this problem. 26 However, there are worries that a bacterial protein might present immunological complications in a human host. Therefore we have investigated the use of mutant versions of hAT that are resistant to inactivation by O 6 -beG and have recently demonstrated that the plasmid-based expression of such mutants can protect an otherwise sensitive cell line against O 6 -alkylating agent cytotoxicity. 19 In order to assess the potential of this approach in a more relevant target cell population, we tested the ability of retrovirally transduced cDNAs encoding hATPA or hATPA/GA proteins to protect human haemopoietic progenitors, in the presence of O 6 -beG, from the toxicity of a variety of O 6 -alkylating agents, including several that are in clinical use. As a prelude to studying primary human CD34
+ cells as targets, retrovirally transduced K562 cells were examined. This allowed the isolation of clonal populations of transduced cells in which it was possible to determine ATase levels using a sensitive biochemical assay, 27 both in the presence and absence of O 6 -beG, and to relate these to the outcome of clonogenic survival assays. Expression of either mutant version of hAT in K562 protected these otherwise sensitive cells from the toxic effects of the methylating agent temozolomide and the chloroethylating agents mitozolomide and chlorozotocin. However, in the clones expressing hATPA, protection against the two chloroethylating agents was essentially abolished by exposure of the cells to O 6 -beG, which is entirely consistent with the degree of depletion of ATase activity observed. Although the hATPA expressing clones were also sensitised to temozolomide toxicity under these conditions, the cells remained significantly resistant relative to controls. This probably reflects the different mechanisms by which O 6 -chloroethylguanine and with the cytosine of the opposite strand, an event which may be fatal for the cell; 28 the crosslink formation is fairly rapid with a proposed half-life of 6 h. Comparatively less is known about cell killing by O 6 -meG. However, it seems likely that the process of cell killing involves either the mismatch repair system 29 or the induction of chain termination events, 30 both of which are dependent on DNA replication. Therefore, it is a possibility that resynthesis of hATPA before DNA replication may allow sufficient repair of O 6 -meG lesions introduced by temozolomide to prevent cell death. Indeed, when the recovery of ATase activity, following depletion by O 6 -beG, was monitored in these cells, the level was found to be 30% of the starting value after 18 h. Importantly, K562 clones expressing hATPA/GA remained resistant to temozolomide, mitozolomide and chlorozotocin in the presence of O 6 -beG (P Ͻ 0.001) thus clearly indicating the efficacy of this approach in haemopoietic progenitors.
We next investigated the utility of the hATPA/GA protein in protecting primary human CD34
+ cells from O 6 -alkylating agent-induced death. Given the data obtained with K562 cells, the single mutant was not further pursued in this study. The transfer of LhATPA/GA into primary human CD34 + cells was highly efficient (up to 70% transduction) and resulted in enhanced protection of these cells from the toxicity of a temozolomide/O 6 -beG combination: approximately 35% clonogenic survival was observed at a dose of both agents that resulted in the survival of less than 1% of control cells. This degree of protection was also observed with the chloroethylating agent mitozolomide: in this instance, 20% of hATPA/GA exposed cells survived a dose of agent that resulted in the death of 96% of control cells. The observation that a different O 6 -beG-resistant hAT mutant (hATGA), reported to be 60-fold less sensitive to the inactivator than hAT, was shown to protect CD34 + cells against BCNU toxicity 31 supports our present findings with mitozolomide and is extended by our further demonstration of methylating agent resistance. Given the present limit of solubility of O 6 -beG, both hATPA/GA and hATGA should retain activity at the maximum serum level of inactivator likely to be achieved in patients. However, if future clinical applications of O 6 -beG involve higher or repeated doses of this agent, or if more soluble derivatives become available allowing higher concentrations of bioavailable drug, it is likely that hATPA/GA-mediated resistance would still be maintained while hATGA might be expected to be inactivated.
In conclusion, this study raises a number of important issues. First, transduction of primary haemopoietic progenitors with hATPA/GA can produce significant, broad-range resistance to O 6 -alkylating agents in the presence of O 6 -beG concentrations that are able to sensitise human tumour xenografts to these drugs. Second, the potential for selection of transduced cells on the basis of ATase expression is encouraging and may be a major influence on the success of this strategy in vivo. Third, the protection afforded against mitozolomide toxicity suggests the possibility that antitumour agents otherwise proscribed because of their myelotoxicity could be reintroduced as clinically effective drugs. However, the analysis of protection of primary human cells in vitro is limited to the bipotent, lineage restricted granulocytemacrophages. For this reason we have developed a murine model in which to assess the potential for the in vivo protection of multipotent murine haemopoietic progenitors by retrovirus-mediated hATPA/GA expression. This first report of multilineage in vivo protection using this approach is described by Chinnasamy et al in the accompanying article in this issue.
Materials and methods

Cell culture
Amphotropic and ecotropic producer cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) (Life Technologies, Paisley, UK) supplemented with 10% new born calf serum (NBCS) (Sigma, Poole, UK) and 2 mm l-glutamine. K562 cells were maintained at an optimal density of 10 5 cells/ml in RPMI (Life Technologies) supplemented with 10% bovine calf serum (BCS) (Sigma), 2 mm l-glutamine. All cells were maintained at 37°C in 5% CO 2 .
Retroviral transduction K562 cells were transduced by daily exposure (4 days) to filtered retroviral supernatant obtained from near confluent packaging cell lines. Transduced cells were maintained for 3 days then plated in semisolid medium and colonies picked into 96-well plates and expanded before PCR for the presence of hAT or hATPA/GA cDNA. PCRpositive colonies were expanded further and ATase activity assayed. Alternatively, transduced populations of cells were exposed to mitozolomide (0.65 g/ml) and after 3 days, surviving cells plated in semisolid medium, scored versus no drug controls and assessed for the presence of hAT cDNA by PCR.
Primary human CD34 + haemopoietic cells were isolated by immunomagnetic separation (Minimacs; Miltenyl Biotech, Bergisch-Gladbach, Germany) of human cord blood. The CD34 + cells (10 5 /ml) were prestimulated in IMDM (Life Technologies) supplemented with 10% FCS, 2 mm l-glutamine, human recombinant IL3 (2 ng/ml), IL6 (100 U/ml) (Sandoz, Basle, Switerzland) and SCF (10 ng/ml) (Amgen, Thousand Oaks, CA, USA), for 3-4 days at 37°C, 5% CO 2 /air in a humidified incubator. The cells, in the same medium plus polybrene (2 g/ml), were then overlayed on a near confluent monolayer of lethally irradiated (60 Gy) amphotropic retroviral packaging cells. After cocultivation (2 days), the nonadherent cells were removed and plated at 3 × 10 3 cells/ml in semisolid medium (IMDM, 20% FCS, 10% 5637 conditioned medium, 0.33% agar) for granulocytemacrophage colony-forming cell (GM-CFC) survival analysis. Cells were also plated in methylcellulose, in order to determine a transduction efficiency for the retrovirus.
PCR analysis of haemopoietic colonies
Individual colonies of K562 cells or GM-CFC were picked using filter tips and either expanded in 96-well plates and then harvested by centrifugation (K562) or dispensed directly into 50 l of K-buffer (1 × Taq polymerase buffer, 0.05% Tween-20, 0.1 mg/ml proteinase-K). Extracts were digested at 56°C for 50 min followed by inactivation of the proteinase-K at 95°C for 10 min. Aliquots (5 l) of these extracts were then used for analysis of transduction frequency by PCR using primers specific for the vector and insert (pLX sense/hAT antisense) as described in the accompanying article. 32 
ATase assay
The ATase assay of PCR-positive K562 colonies was performed as previously described. 27 Inactivation of the ATase proteins in vitro in K562 cells was also as described, 19 -alkylating agent studied. Cells were preincubated in plating medium (RPMI (10% FCS, 2 mm l-glutamine)) supplemented with 10% BSA to which was added molten agar to a final concentration of 0.33% immediately before plating in dishes containing an appropriate amount of O 6 -alkylating agent in an equal final volume of DMSO. Survival was determined by scoring surviving colonies (percentage) against the no drug controls for each agent. In the absence of any agent, around 100 colonies per plate were routinely seen.
Statistical analysis
The data were analysed for statistical significance using an analysis of variance test (MINITAB State College, PA, USA) for colony-forming survival assays. In all cases the accepted probability value for significance is P Ͻ 0.001, and a probability value of P Ͼ 0.05 has been determined as non-significant. For the analysis of CD34 + cells, a paired student's t test was used to analyse individual data points and a value of P Ͼ 0.05 determined as nonsignificant.
